The biotechnology industry has witnessed significant shifts in recent years, particularly in the realm of both mergers and acquisitions (M&A) and collaborative agreements. These trends are driven by various strategic and financial considerations from both established pharmaceutical companies and development-stage biotech firms. Understanding the valuation and accounting implications of these transactions are crucial for stakeholders to navigate the complex landscape effectively.
Read the full article: Valuation of Biotech Transactions: Trends, Drivers, and Implications //
Source: https://medcitynews.com/2024/08/valuation-of-biotech-transactions-trends-drivers-and-implications/